Berenberg announced Thursday that it has raised its price target for Eurofins Scientific from €65 to €69, while renewing its buy recommendation on the stock.

In a note, the analyst stresses that now that revenues linked to the Covid epidemic have returned to zero, investors will once again be able to focus on the core businesses of the French bio-analysis giant.

In this respect, the intermediary says it expects sales for 2024 to be 1% above current consensus projections, and adjusted Ebitda to be 1.6% above market forecasts, due to the operating leverage it believes the Group enjoys.

Copyright (c) 2024 All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.